ScreenPoint Medical’s Transpara breast imaging AI solution will be used in a study evaluating the role of artificial intelligence (AI) in breast cancer screening.

Funded by the Patient-Centered Outcomes Research Institute (PCORI), Transpara has been chosen as the technology of choice in the PRISM (Pragmatic Randomized Trial of Artificial Intelligence for Screening Mammography) trial. ScreenPoint Medical claims PRISM is the first large-scale U.S. trial to rigorously assess AI’s impact on breast cancer screening.

Led by UCLA and UC Davis, the PRISM trial will study whether AI can help radiologists detect breast cancer earlier, improve mammography accuracy, and reduce unnecessary patient callbacks. Furthermore, the trial will include focus groups and surveys to capture the patient experience and assess the perception of artificial intelligence for both clinicians and patients.

Fueled by a $16 million award, the study will involve hundreds of thousands of mammograms interpreted at academic medical centers including UCLA, UC Davis, UC San Diego, Boston Medical Center, University of Miami, University of Washington/Fred Hutchinson Cancer Center, and University of Wisconsin–Madison. ScreenPoint Medical’s Transpara Detection software will be used as part of the study protocol with clinical workflow integration provided by the Aidoc aiOS platform.

“This landmark trial attests to three pillars: the pioneering vision of the researchers involved, PCORI’s forward-thinking perspective on technology, and the potential of AI to help radiologists shape a healthier future,” ScreenPoint Medical CEO Pieter Kroese stated. “We are honored that Transpara was selected for the PRISM Trial. We are equally proud to support academic medical centers and breast imaging facilities in advancing earlier breast cancer detection as well as more patient-centered and personalized systems of care.”

Backed by a proven, prospective, and persuasive track record of breast imaging AI research, ScreenPoint Medical’s Transpara Breast AI is used across imaging service lines, academic institutions, and screening programs worldwide, with more than 10 million mammograms analyzed to date. Transpara aims to enhance accuracy, improve consistency, and maximize efficiency while ensuring physicians remain central to every decision.

ScreenPoint Medical builds AI-powered technology for every step of the breast imaging continuum, improving consistency, reducing uncertainty, enhancing patient experience, and translating opportunity into tangible outcomes.